Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1591
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3015    
    Printed58    
    Emailed1    
    PDF Downloaded507    
    Comments [Add]    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2014  |  Volume : 51  |  Issue : 7  |  Page : 86-91

The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: A meta-analysis from randomized controlled clinical trials


1 School of Pharmaceutical Science, Peking University, Beijing 100191, China
2 School of Public Health; International Research Center of Medicinal Administration, Peking University, Beijing 100191, China
3 China National Center for Biotechnology Development, Beijing 100039, China
4 School of Pharmaceutical Science; International Research Center of Medicinal Administration, Peking University, Beijing 100191, China

Correspondence Address:
L W Shi
School of Pharmaceutical Science; International Research Center of Medicinal Administration, Peking University, Beijing 100191
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-509X.154070

Rights and Permissions

Background: The extent of the benefit of gefitinib in the treatment of advanced nonsmall-cell lung cancer (NSCLC) is till controversial, when compared with docetaxel. We performed this meta-analysis to compare the efficacy and toxicity of gefitinib with docetaxel for different patients with advanced NSCLC. Materials and Methods: We searched PubMed, Cochrane Library, and identified 5 randomized controlled clinical trials published within 2000-2013. After further full-text screening, 4 clinical trials were included in the final meta-analysis. Results: The outcomes of treatment efficacy included progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Comparing gefitinib to docetaxel for advanced NSCLC patients, the pooled hazard ratio (HR) of PFS was 0.91, (95% confidential index [CI] = 0.83-0.99), the pooled HR of OS was 1.02, (95% CI = 0.93-1.13), the pooled risk ratio of ORR was 1.57, (95% CI = 1.01-2.47). Conclusions: Gefitinib was found to significantly improve patients' PFS and response rate compared with docetaxel. There is no difference of OS between gefitinib and docetaxel.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow